[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607507":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":55,"collaborators":25,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":25,"overallStatus":43,"whyStopped":25,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ZG006","EXPERIMENTAL","ZG006 10 mg Q2W",[13],"Drug: ZG006",{"label":15,"type":16,"description":17,"interventionNames":18},"Investigator-Selected Chemotherapy","ACTIVE_COMPARATOR","Investigator-selected chemotherapy, such as topotecan.",[19],"Drug: Topotecan",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","ZG006 will be administered as an intravenous (IV) infusion.",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Topotecan","Topotecan will be administered per local standard of care",[15],[31],{"name":32,"affiliation":5,"role":33},"Jason Wu","STUDY_CHAIR",[35],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Hewen Yin","CONTACT","+86-0512-57309965","yinhw@zelgen.com",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":25},"Shanghai Chest Hospital","RECRUITING","Shanghai","Shanghai Municipality","200030","China","CN",{"type":50,"coordinates":51},"Point",[52,53],121.45806,31.22222,{"lat":53,"lon":52},{"type":56,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100607507","phase-3-study-comparing-zg006-with-investigator-selected-chemotherapy-in-participants-with-relapsed-small-cell-lung-cancer-100607507",false,"NCT07189455","Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer","A Multicenter, Randomized, Controlled, Open-Label Phase III Study Evaluating the Efficacy and Safety of ZG006 for Injection Compared With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer","Inclusion Criteria:\n\n* Fully understand the study and voluntarily sign the informed consent form;\n* Male or female 18\\~75 years of age;\n* Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1;\n* Life expectancy ≥ 3 months;\n* Histologically or cytologically confirmed Small Cell Lung Cancer.\n\nExclusion Criteria:\n\n* Participants were deemed unsuitable for participating in the study by the investigator for any reason.","ALL","18 Years","75 Years",{"count":68,"type":69},420,"ESTIMATED","INTERVENTIONAL",[72],"PHASE3","The main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).",[75],"Small-cell Lung Cancer","2025-12-30",{"date":78,"type":79},"2026-01-05","ACTUAL",{"date":81,"type":79},"2025-12-12",{"date":83,"type":69},"2028-12",{"name":5,"class":6},1]